Perceived Pain Following Hypnotic Deprescribing in Older Adults

Read full text
Authors: Jennifer G. Hurtado, Alexander J. Erickson, Michael N. Mitchell, Jennifer L. Martin, Cathy Alessi, Joseph M. Dzierzewski, Sara Ghadimi, Erin Der‐Mcleod, Claudia Perdomo, Saadia Naeem, Adrienne Moore, M. Safwan Badr
+2 more Michelle R. Zeidler, Constance H. Fung
Cited by: 0
References: 20

Abstract

BACKGROUND: Older adults with chronic insomnia often use benzodiazepine receptor agonists (BZRAs) despite known associated risks and non-pharmacological alternatives such as cognitive behavioral therapy for insomnia (CBTI). CBTI reduces insomnia severity and could potentially improve other outcomes such as the impact of pain on daily activities, even when BZRAs are deprescribed. Yet concerns that deprescribing may worsen pain (which is often comorbid with insomnia) can be a barrier to engagement in BZRA deprescribing. This study examined changes in pain outcomes associated with deprescribing BZRAs in the context of concurrent CBTI. METHODS: Secondary data analysis was conducted using data from a randomized clinical trial that successfully decreased BZRA use in older adults. Participants (n = 188), who were largely older (68% ≥ 65 years, 55 ≤ range ≤ 91) and male (65%), completed CBTI concurrently with a deprescribing intervention (blinded encapsulated BZRA taper or open pill cutter taper). Participants completed the Brief Pain Inventory (BPI) at baseline, one week posttreatment (1 WK), and at a six-month (6 M) follow-up. Analyses included mixed effects models among all participants and a subset aged 65+ as well as comparison of model results to minimal clinically important difference (MCID) thresholds. RESULTS: Mixed effects models demonstrated that pain severity did not change significantly over time, broadly or in participants aged ≥ 65 years. Significant reductions in pain interference in day-to-day living at 1 WK were observed broadly, although these reductions did not meet the MCID threshold and were no longer significant at 6 M follow-up. CONCLUSIONS: Combined BZRA deprescribing and CBTI did not meaningfully worsen pain in older adults. These results highlight the opportunity for using a combination of CBTI and deprescribing methods in patients with insomnia and comorbid pain, as well as a need for additional interventions to specifically address pain in older adults with chronic insomnia.

Fields of Study & Subjects

Sleep and related disorders Pharmaceutical Practices and Patient Outcomes Pain Management and Opioid Use

Publication details

Journal / source
Journal of the American Geriatrics Society
Volume
74
Issue
3
Pages
669–675
Publication date
10 January 2026
Language
EN